Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24477395 | 0.98 | TP53 (0.31) | TP53PKMKDM4EALDH1A1 | |
| SCHEMBL23419697 | 0.93 | KDM4E (0.36) | TP53PKMKDM4EALDH1A1 | |
| SCHEMBL8909113 | 0.83 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL10081279 | 0.81 | ALDH1A1 (0.48) | KDM4EALDH1A1 | |
| SCHEMBL25565768 | 0.81 | CHRM2 (0.39) | TP53PKMKDM4EALDH1A1 | |
| SCHEMBL25565770 | 0.79 | CHRM2 (0.37) | KDM4EALDH1A1 | |
| SCHEMBL8579206 | 0.77 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL4609242 | 0.77 | ALDH1A1 (0.41) | KDM4EALDH1A1 | |
| SCHEMBL25101935 | 0.76 | SLC6A2 (0.38) | — | |
| SCHEMBL5159311 | 0.74 | ALDH1A1 (0.40) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022268229-A1 | PROTEIN INHIBITOR OR DEGRADING AGENT, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PHARMACEUTICAL USE | 和径医药科技（上海）有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-20220169660-A1 | CYCLIC AMINO-PYRAZINECARBOXAMIDE COMPOUNDS AND USES THEREOF | SILVERBACK THERAPEUTICS INC (US) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169660-A1 | CYCLIC AMINO-PYRAZINECARBOXAMIDE COMPOUNDS AND USES THEREOF | TGFBR2, ACVR2A, SMAD2 | TP53 362/4885PKM 2958/4885KDM4E 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.